Usama Malik, Chief Financial Officer and Chief Business Officer, Immunomedics discusses the challenges of developing effective medicines for people with triple negative breast cancer as well as Immunomedics’ development of antibody-drug conjugates, directed therapies which have potential to provide new options for those with hard to treat cancers.